Oncolys BioPharma nine-month net loss narrows 31% to JPY 1.12 billion; nine-month net sales rise to JPY 527.81 million

Bitget2026/11/06 06:44

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncolys BioPharma narrowed its net loss 31% year-over-year to JPY 1.12 billion for the nine months ended September 30, 2026.
Net sales rose year-over-year to JPY 527.81 million.
Telomelysin Injection secured full marketing approval in Japan and launched in August 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolys BioPharma Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncolys BioPharma nine-month net loss narrows 31% to JPY 1.12 billion; nine-month net sales rise to JPY 527.81 million

You may also like

Crypto prices